Improving therapeutic properties of protein drugs through alteration of intracellular trafficking pathways

Biotechnology Progress

Volumn 24, Issue 1, 2008, Pages 2-7

  Lao, Bert J ^a   Kamei, Daniel T ^a  

^a University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; PROTEINS;

CELLULAR ASSOCIATION; INTRACELLULAR TRAFFICKING PATHWAYS; MOLECULAR DESIGN;

DRUG PRODUCTS;

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN; TRANSFERRIN;

BIOLOGICAL MODEL; CONFERENCE PAPER; METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

GRANULOCYTE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, BIOLOGICAL; PROTEIN TRANSPORT; PROTEINS; SIGNAL TRANSDUCTION; TRANSFERRIN;

EID: 38949188650     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070080b     Document Type: Conference Paper

References (30)

1. Lauffenburger, D. A.; Linderman, J. J. Receptors; Oxford University Press: New York 1993; pp 1-365.
2. Weaver, M.; Laske, D. W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 2003, 65, 3-13.
3. Duhrsen, U.; Villeval, J. L.; Boyd, J.; Kannourakis, G.; Morstyn, G.; Metcalf, D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72, 2074-2081.
4. Bradley, P.; Misura, K. M.; Baker, D. Toward high-resolution de novo structure prediction for small proteins. Science 2005, 309, 1868-1871.
5. Morell, A.; Terry, W. D.; Waldmann, T. A. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 1970, 49, 673-680.
6. Gabrilove, J. L.; Jakubowski, A.; Fain, K.; Grous, J.; Scher, H.; Sternberg, C.; Yagoda, A.; Clarkson, B.; Bonilla, M. A.; Oettgen, H. F.; et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J. Clin. Invest. 1988, 82, 1454-1461.
7. Shetty, P. S.; Watrasiewicz, K. E.; Jung, R. T.; James, W. P. Rapid-turnover transport proteins: an index of subclinical protein-energy malnutrition. Lancet 1979, 2, 230-232.
8. Ghetie, V.; Ward, E. S. Multiple roles for the major histocompatibility complex class 1- related receptor FcRn. Annu. Rev. Immunol. 2000, 18, 739-766.
9. Martin, W. L.; West, A. P., Jr.; Gan, L.; Bjorkman, P. J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 2001, 7, 867-877.
10. Raghavan, M.; Bonagura, V. R.; Morrison, S. L.; Bjorkman, P. J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995, 34, 14649-14657.
11. Zheng, X. X.; Steele, A. W.; Hancock, W. W.; Kawamoto, K.; Li, X. C.; Nickerson, P. W.; Li, Y.; Tian, Y.; Strom, T. B. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 1999, 163, 4041-4048.
12. Dall'Acqua, W. F.; Woods, R. M.; Ward, E. S.; Palaszynski, S. R.; Patel, N. K.; Brewah, Y. A.; Wu, H.; Kiener, P. A.; Langermann, S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 2002, 169, 5171-5180.
13. Hinton, P. R.; Johlfs, M. G.; Xiong, J. M.; Hanestad, K.; Ong, K. C.; Bullock, C.; Keller, S.; Tang, M. T.; Tso, J. Y.; Vasquez, M.; Tsurushita, N. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 2004, 279, 6213-6216.
14. Kamei, D. T.; Lao, B. J.; Ricci, M. S.; Deshpande, R.; Xu, H.; Tidor, B.; Lauffenburger, D. A. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol. Bioeng. 2005, 92, 748-760.
15. Sarkar, C. A.; Lauffenburger, D. A. Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Mol. Pharmacol. 2003, 63, 147-158.
16. French, A. R. D. A. L. Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol. Bioeng. 1996, 51, 281-297.
17. French, A. R.; Lauffenburger, D. A. Controlling receptor/ligand trafficking: effects of cellular and molecular properties on endosomal sorting. Ann. Biomed. Eng. 1997, 25, 690-707.
18. Carlton, J.; Bujny, M.; Rutherford, A.; Cullen, P. Sorting nexins - unifying trends and new perspectives. Traffic 2005, 6, 75-82.
19. Zheng, B.; Lavoie, C.; Tang, T. D.; Ma, P.; Meerloo, T.; Beas, A.; Farquhar, M. G. Regulation of epidermal growth factor receptor degradation by heterotrimeric Galphas protein. Mol. Biol. Cell 2004, 15, 5538-5550.
20. Sarkar, C. A.; Lowenhaupt, K.; Horan, T.; Boone, T. C.; Tidor, B.; Lauffenburger, D. A. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 2002, 20, 908-913.
21. Aritomi, M.; Kunishima, N.; Okamoto, T.; Kuroki, R.; Ota, Y.; Morikawa, K. Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Nature 1999, 401, 713-717.
22. Aisen, P.; Listowsky, I. Iron transport and storage proteins. Annu. Rev. Biochem. 1980, 49, 357-393.
23. Hentze, M. W.; Muckenthaler, M. U.; Andrews, N. C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117, 285-297.
24. Cazzola, M.; Bergamaschi, G.; Dezza, L.; Arosio, P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990, 75, 1903-1919.
25. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561-587.
26. Yazdi, P. T.; Murphy, R. M. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res. 1994, 54, 6387-6394.
27. Lao, B. J.; Tsai, W. L.; Mashayekhi, F.; Pham, E. A.; Mason, A. B.; Kamei, D. T. Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J. Controlled Release 2007, 117, 403-412.
28. Rao, B. M.; Lauffenburger, D. A.; Wittrup, K. D. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 2005, 23, 191-194.
29. Cheng, Y.; Zak, O.; Aisen, P.; Harrison, S. C.; Walz, T. Structure of the human transferrin receptor-transferrin complex. Cell 2004, 116, 565-576.
30. Halbrooks, P. J.; Mason, A. B.; Adams, T. E.; Briggs, S. K.; Everse, S. J. The oxalate effect on release of iron from human serum transferrin explained. J. Mol. Biol. 2004, 339, 217-26.